What this study is
The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.
What's being tested
- Tumor biopsy
Intervention · PROCEDURE
For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
- Phlebotomy
Intervention · PROCEDURE
Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
Study details
- Sponsor
- Stanford University
- Conditions
- Head and Neck Cancer · Lung Cancer · Lip Cancer · Lip Neoplasms · Head and Neck Cancers
- Enrolling
- 200 people
- Starts
- 1998-09-01
- Est. completion
- 2027-06-30
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
- Able to sign a Stanford IRB approved consent form
You can't join if
- Refuse or unable to sign an IRB approved consent form.
- Refuse to be contacted in the future for follow up.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openStanford University School of Medicine
Stanford, California, United States
- Eyiwunmi Laseinde · ContactRad-onc-ccto@lists.stanford.edu
- Cancer Clinical Trials Office · Contact(650) 498-7061
- Quynh-Thu Le · Principal investigator
- Amato Giaccia · Sub-investigator
- Richard L Goode · Sub-investigator
- Harlan Pinto · Sub-investigator
- Dr. Billy W. Loo Jr. M.D. Ph.D. · Sub-investigator
Recruiting
Study team
Sponsor
Stanford University
Study ID IRB-10564
Principal investigator
Quynh-Thu Le
Stanford University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.